Abstract P146 – Table 1. CVD risk prediction strata according to different CVD risk prediction modelsa. | |||||
---|---|---|---|---|---|
n = 1132 | |||||
ASCVD | Low risk (<5%) n (%) | Borderline risk (5% to 7.5%) n (%) | Intermediate risk (7.5% to 20%) n (%) | High risk (≥20%) n (%) | |
459 (40.5) | 189 (16.7) | 378 (33.4) | 106 (9.4) | ||
FRS‐CVD 10 year | Low risk (<10%) n (%) | Moderate risk (10% to 20%) n (%) | High risk (≥20%) n (%) | ||
464 (41) | 372 (32.9) | 296 (26.1) | |||
Modified Framingham | 728 (64.3) | 304 (26.9) | 100 (8.8) | ||
<1% n (%) | 1% to 5% n (%) | 5% to 10% n (%) | >10% n (%) | ||
D:A:D‐reduced 5 year | 62 (5.5) | 651 (57.5) | 276 (24.4) | 143 (12.6) | |
D:A:D‐reduced 10 year | 8 (0.7) | 319 (28.2) | 375 (33.1) | 430 (38) | |
SCORE2/SCORE2‐OP for high risk countries | Low‐moderate n (%) | High risk n (%) | Very high risk n (%) | ||
320 (28.3) | 615 (54.3) | 197 (17.4) |
ASCVD, Atherosclerotic Cardiovascular Disease; FRS‐CVD, Framingham Heart Study General CVD; D:A:D, Data Collection on Adverse Events of Anti‐HIV Drugs; SCORE2, Systemic Coronary Risk Evaluation Score 2; SCORE2‐OP, SCORE2‐Older Persons.
aPatients were considered at higher risk if their 10‐year CVD risk was >20% for FRS‐CVD and Mod‐FRS, >20% for ASCVD, 5‐year risk >10% for D:A:D and high/very high risk for SCORE2 for high‐risk countries.